REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2020.08.04 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma - HTML (w)

2020.08.03 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis - HTML (w)

2020.07.27 | 09:29 | Permanent Information Releases / General Company News

puce Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe - HTML (w)

2020.07.24 | 13:36 | Permanent Information Releases / General Company News

puce Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease - HTML (w)

2020.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt. - HTML (w)

2020.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales. - HTML (w)

2020.07.21 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires. - HTML (w)

2020.07.16 | 07:15 | Permanent Information Releases / General Company News

puce Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 - HTML (w)

2020.07.07 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU - HTML (w)

2020.07.02 | 00:41 | Permanent Information Releases / General Company News

puce Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies - HTML (w)

2020.07.01 | 18:13 | Permanent Information Releases / General Company News

puce Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case - HTML (w)

2020.06.29 | 08:45 | Permanent Information Releases / General Company News

puce Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options - HTML (w)

2020.06.26 | 13:37 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile - HTML (w)

2020.06.26 | 13:21 | Permanent Information Releases / General Company News

puce Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps - HTML (w)

2020.06.25 | 19:11 | Permanent Information Releases / General Company News

puce Novartis Resolves Legacy FCPA Investigations - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1339